BioSpace News Archive

The National Institutes of Health has granted an NIH Director’s New Innovator Award to Seth Shipman, PhD, assistant investigator at Gladstone Institutes.

KBL Merger Corp. IV (NASDAQ: KBLM or the “Company”), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive agreement to acquire 180 Life Sciences Corp. (“180 Life Sciences”), today announced that 180 Sciences Corp. continues to expand their robust IP portfolio.

More than a dozen states1 now allow recreational marijuana use, and millions of adults use e-cigarettes regularly2, but surgeons warn that even as these products become more widely available, they can be harmful if used before an operation.

Endo International plc (NASDAQ: ENDP) today announced the release of its first Environmental, Social and Governance (ESG) report, titled 2019 Corporate Responsibility Report: Helping Everyone We Serve Live Their Best Life.

ZERO TO THREE, the leading nonprofit dedicated to ensuring all babies and toddlers have a strong start in life, announced today the first-ever winners of the Infant and Early Childhood Mental Health (IECMH) Emerging Leadership Award, honoring two emerging leaders in the field of infant and early childhood mental health.

The following quote is attributed to Peter Marks , M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research: “Being open and clear about the circumstances under which the issuance of an emergency use authorization for a COVID-19 vaccine would be appropriate is critical to building public confidence a

Indago, LLC, a medical device and technology company, announces that Leah Brownlee, J.D., has been appointed as President and General Counsel. Ms. Brownlee, an experienced life science executive, most recently served in the Corporate Practice and Life Sciences Industry groups at Squire Patton Boggs and previously served as Executive Vice President of Compliance and Operations at Cleveland BioLabs, Inc., a clinical-stage NASDAQ-

AbFero Pharmaceuticals, Inc. , a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced it completed analysis of a 12-patient normal volunteer pharmacokinetic (PK) trial of its lead iron chelator, SP-420. The PK data confirmed that the doses of SP-420 planned for the company’s

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that its Board of Directors has formed a Special Committee to oversee and advise the executive leadership team on the operations of the Co

C4 Therapeutics , Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public offering of 11.04 million shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1.44 million additional shares of common stock, at a public offering price o